Brokerages Set OptimizeRx Co. (NASDAQ:OPRX) Price Target at $11.58

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $10.42.

A number of research firms have commented on OPRX. B. Riley began coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They issued a “buy” rating and a $18.50 target price on the stock. Barclays cut their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday. Royal Bank of Canada decreased their target price on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday. William Blair restated an “outperform” rating on shares of OptimizeRx in a report on Thursday. Finally, Roth Mkm restated a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research note on Thursday.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC raised its position in OptimizeRx by 5.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after buying an additional 89,377 shares during the last quarter. Vanguard Group Inc. increased its position in OptimizeRx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after purchasing an additional 6,291 shares during the period. AWM Investment Company Inc. raised its stake in shares of OptimizeRx by 4.0% during the 1st quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock worth $10,364,000 after buying an additional 33,000 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of OptimizeRx by 5.6% in the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after buying an additional 41,469 shares during the period. Finally, Rice Hall James & Associates LLC grew its holdings in OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after acquiring an additional 119,306 shares during the period. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Trading Down 5.8 %

Shares of OptimizeRx stock opened at $3.83 on Thursday. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The firm has a market capitalization of $70.07 million, a price-to-earnings ratio of -2.88 and a beta of 1.32. The stock has a 50 day moving average of $6.60 and a 200 day moving average of $8.98.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.